Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.70 |
| ▸ | CHUK | O15111 | 5/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.70 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.70 |
| ▸ | PAK4 | O96013 | 1/20 | 0.70 |
| ▸ | CSF1R | P07333 | 1/20 | 0.70 |
| ▸ | RET | P07949 | 1/20 | 0.70 |
| ▸ | IGF1R | P08069 | 1/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.70 |
| ▸ | PRKACA | P17612 | 1/20 | 0.70 |
| ▸ | FLT1 | P17948 | 1/20 | 0.70 |
| ▸ | LTK | P29376 | 1/20 | 0.70 |
| ▸ | GRK5 | P34947 | 1/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.70 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4792683 | 0.90 | NUDT1 (0.63) | IKBKBCHUKAURKBROCK1DAPK3 | |
| SCHEMBL4790931 | 0.89 | IKBKB (0.57) | IKBKBCHUKAURKBROCK1DAPK3 | |
| SCHEMBL4790758 | 0.89 | IKBKB (0.58) | IKBKBCHUKAURKBROCK1DAPK3 | |
| SCHEMBL30009307 | 0.88 | IKBKB (0.68) | IKBKBCHUKAURKBROCK1DAPK3 | |
| SCHEMBL4792307 | 0.88 | IKBKB (0.56) | IKBKBCHUKAURKBROCK1DAPK3 | |
| SCHEMBL4791911 | 0.88 | IKBKB (0.56) | IKBKBCHUKAURKBROCK1DAPK3 | |
| SCHEMBL4791930 | 0.88 | IKBKB (0.56) | IKBKBCHUKAURKBROCK1DAPK3 | |
| SCHEMBL4790909 | 0.86 | IKBKB (0.56) | IKBKBCHUKAURKBROCK1DAPK3 | |
| SCHEMBL4792515 | 0.86 | IKBKB (0.56) | IKBKBCHUKAURKBROCK1DAPK3 | |
| SCHEMBL4794299 | 0.86 | IKBKB (0.52) | IKBKBCHUKAURKBROCK1DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979353-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | claimed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | claimed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | claimed |
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-11-27 | — | — | US | disclosed |
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-1979353-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | LATS2, LATS1, AKT1S1 | IKBKB 405/4885CHUK 48/4885AURKB 842/4885 |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | MAP2K5, MAP2K7, MAP2K2 | IKBKB 138/4885CHUK 31/4885AURKB 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.